Edgewise Therapeutics Up 47%, Announces Topline Phase 1 and 2 Data for Heart Disease Treatment
Edgewise Therapeutics Up 47%, Announces Topline Phase 1 and 2 Data for Heart Disease Treatment
$Edgewise Therapeutics (EWTX.US)$ is up 47% in midday trading after announcing top-line data of EDG-7500 from its Phase 1 trial; the drug is designed to improve heart function in cardiomyopathy patients.
$Edgewise Therapeutics (EWTX.US)$ 在午盘交易中，股票上涨了47％，宣布EDG-7500的一期试验的顶线数据；这种药物旨在改善心肌病患者的心脏功能。
“Based on the strength of clinical and preclinical data to-date, we have initiated the 28-day part of CIRRUS-HCM in patients with obstructive and non-obstructive HCM,” said Marc Semigran, M.D., Chief Development Officer, Edgewise Therapeutics, in a press release. “Importantly, we plan to continue the evaluation of tolerability, pharmacokinetics and effects on LVOT-G, LVEF, biomarkers and measures of feel and function in these patients.”
“根据迄今为止的临床和临床前数据的强大实力，我们已经在梗阻性和非梗阻性HCm患者中启动了CIRRUS-HCm的为期28天的部分，” Edgewise Therapeutics的首席发展官Marc Semigran万.D.在新闻发布会上表示。“重要的是，我们计划继续评估这些患者的耐受性，药代动力学以及对LVOt-G，LVEF，生物标志物和感受和功能的影响。”
In a separate Phase 2 single-dose trial for patients with obstructive hypertrophic cardiomyopathy (HCM)--a common cause of heart disease in young people--the company also shared positive data and expects to report initial 28-day data in the first quarter of 2025.
在一项针对患有梗阻性肥厚型心肌病（HCM）的患者的单剂量二期试验中，该公司还分享了积极的数据，并预计将在2025年第一季度报告初步的28天数据。这是年轻人心脏病的常见原因。